|
The
ViewFlex catheter offers bi-directional
steering and easy one-handed operation. The
transducer tip features a 64-element linear phased
array that provides excellent image quality capable
of resolving most detailed cardiac anatomic
structure and treatment devices. The transducer’s
range of frequencies allows both high resolution
and penetration to imaging depths desired in
advanced procedures such as ablation treatment of
atrial fibrillation, where accurate visualization of
the entire left atrial and pulmonary vein anatomy is
desired.
–
end –
About EP MedSystems:
EP MedSystems develops and
markets cardiac electrophysiology ("EP") products
used to diagnose and treat certain cardiac rhythm
disorders. The Company's EP product line includes
the EP-WorkMate® Electrophysiology Workstation with
RPM(TM) Real-time Position Management(TM) navigation
technology, the EP-4(TM) Computerized Cardiac
Stimulator, fixed and deflectable diagnostic
electrophysiology catheters and related disposable
supplies, the ALERT® System and ALERT family of
internal cardioversion catheters, and the ViewMate®
intracardiac ultrasound catheter imaging system. For
more information, visit our website at
www.epmedsystems.com.
About Royal Philips Electronics:
Royal Philips Electronics of the Netherlands
(NYSE: PHG, AEX: PHI) is a global leader in
healthcare, lifestyle and technology, delivering
products, services and solutions through the brand
promise of “sense and simplicity”. Headquartered in
the Netherlands, Philips employs approximately
126,000 employees in more than 60 countries
worldwide.
With sales of $37.7
billion (EUR 30.4 billion) in 2005,
the company is a market leader in medical diagnostic
imaging and patient monitoring systems, energy
efficient lighting solutions, personal care and home
appliances, as well as consumer electronics. News
from Philips is located at
www.philips.com/newscenter.
Forward Looking Statements:
This Release may contain
certain statements of a forward-looking nature
relating to future events or the future financial
performance of the Company. Forward-looking
statements include information concerning our
possible or assumed future results of operations and
statements preceded by, followed by or including the
words "believes", "expects", "anticipates",
"intends", "plans", "estimates", "see opportunities"
or similar expressions. Such forward-looking
statements are based on our management's beliefs and
assumptions and on information currently available
to our management. Such forward-looking statements
are only predictions and are subject to risks and
uncertainties that could cause actual results or
events to differ materially and adversely from the
events discussed in the forward-looking statements.
Factors that could cause or contribute to such
differences include, but are not limited to, EP
MedSystems' history of losses, uncertainty of market
acceptance of our products and level of sales,
uncertainty of future profitability and future
liquidity needs, possible costs, fines or penalties
that may be incurred in connection with government
inquiries and investigations and risks regarding
regulatory approvals and demand for new and existing
products, as stated in the Company's Annual Report
filed on Form 10-K and Quarterly Reports filed on
Form 10-Q.
EP MedSystems cautions investors
and others to review the cautionary statements set
forth in this press release and in EP MedSystems'
reports filed with the Securities and Exchange
Commission and cautions that other factors may prove
to be important in affecting the EP MedSystems'
business and results of operations. Readers are
cautioned not to place undue reliance on this press
release and other forward-looking statements, which
speak only as of the date of this release. EP
MedSystems undertakes no obligation to publicly
release the results of any revisions to these
forward-looking statements that may be made to
reflect events or circumstances after the date of
this report or to reflect the occurrence of
unanticipated events.
###
|
